SAN DIEGO,CA (Oct. 21, 2020) ­– Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today initiation of a Phase 2 clinical trial of OXE103 for treating concussion.

Concussion Alliance Interviews the CEO of Oxeia, Michael Wyand and co-founder and chief scientific officer, Dr. Vishal Bansal on the company’s work developing a drug treatment for concussion.

Oxeia's Chief Scientific Officer Vishal Bansal shared his knowledge of the science behind concussions, as well as his hopes for future treatments on "Recovery Now," on the Brain Injury Network. Dr. Bansal told the host, Kim Justus, that the drug Oxeia is developing for treating concussions is targeting the 20% of concussion sufferers who don't recover in 28 days from their injury.

Concussions are a serious health problem in the military. In January, 2020, 109 US servicemen in Iraq suffered traumatic brain injury from Iranian airstrikes. But this is just the latest occurrence; in the last 9 years over 413,000 troops were diagnosed with TBI.

In this article, Oxeia co-founder and chief scientific officer, Vishal Bansal, calls on Congress, the Pentagon, and the medical establishment to increase their commitment to finding an effective treatment to protect our proud members of the military.

Oxeia Biopharmaceuticals' CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference in London in December. Oxeia is preparing for the launch of Phase 2 human clinical studies for its therapeutic drug to treat concussions.

49ers star Richard Sherman is betting on software and against concussions as he dives into start-ups. One of the startups is Oxeia Biopharmaceuticals, which is developing a concussion drug that would treat the immediate symptoms and the underlying damage.

San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.

Oxeia Biopharmaceuticals Inc. announces the appointment of Michael Wyand, DVM, PhD as Chief Executive Officer. Dr. Wyand will also join Oxeia’s Board of Directors.

NFL All-Pro Richard Sherman joins Oxeia board as it readies phase 2 concussion drug research

Oxeia Biopharmaceuticals Inc. announces Richard Sherman, cornerback of the Seattle Seahawk’s (National Football League), as a member of its Advisory Board.

Oxeia Biopharmaceuticals Inc., announces its acquisition of the license to SUN11031, synthetic human ghrelin, from Kinemed Inc. Oxeia will develop SUN11031 as OXE103 to treat concussions and other acute neurotrauma.